Evidence map›Paper›PMID 39807561›Full record

ArticleJournal of the American Chemical Society2025

Ni-Catalyzed Enantioselective Desymmetrization: Development of Divergent Acyl and Decarbonylative Cross-Coupling Reactions.

Ángel D Hernández-Mejías, Alexander M Shimozono, Avijit Hazra, Sven Richter, Zhengjia Tong, Neil F Langille, Kyle Quasdorf, Andrew T Parsons, Matthew S Sigman, Sarah E Reisman

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Ring-opening decarbonylative C(spChemical science · 2026
    Article
  3. Article
  4. Article
  5. Aryl Acid-Alcohol Cross-Coupling: C(spJournal of the American Chemical Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ángel D Hernández-MejíasThe Warren and Katharine Schlinger Laboratory for Chemistry and Chemical Engineering, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States.ORCID 0000-0002-1039-4790
Alexander M ShimozonoThe Warren and Katharine Schlinger Laboratory for Chemistry and Chemical Engineering, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States.ORCID 0000-0001-7164-4741
Avijit HazraDepartment of Chemistry, University of Utah, Salt Lake City, Utah 84112, United States.
Sven RichterThe Warren and Katharine Schlinger Laboratory for Chemistry and Chemical Engineering, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States.
Zhengjia TongThe Warren and Katharine Schlinger Laboratory for Chemistry and Chemical Engineering, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States.
Neil F LangilleDrug Substance Technologies - Synthetics, Amgen, Inc., 360 Binney St, Cambridge, Massachusetts 02142, United States.
Kyle QuasdorfDrug Substance Technologies - Synthetics, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320 United States.ORCID 0000-0003-0151-6511
Andrew T ParsonsDrug Substance Technologies - Synthetics, Amgen, Inc., 360 Binney St, Cambridge, Massachusetts 02142, United States.ORCID 0000-0002-0320-0919
Matthew S SigmanDepartment of Chemistry, University of Utah, Salt Lake City, Utah 84112, United States.ORCID 0000-0002-5746-8830
Sarah E ReismanThe Warren and Katharine Schlinger Laboratory for Chemistry and Chemical Engineering, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States.ORCID 0000-0001-8244-9300

Funding

Chemical Synthesis of Chiral Bioactive MoleculesR35GM118191 · NIGMS · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI Sarah Elizabeth Reisman · 2016 to 2026
$6.6M
NIGMS NIH HHS R35 GM118191
6 · The paper itself

Abstract

Ni-catalyzed asymmetric reductive cross-coupling reactions provide rapid and modular access to enantioenriched building blocks from simple electrophile precursors. Reductive coupling reactions that can diverge through a common organometallic intermediate to two distinct families of enantioenriched products are particularly versatile but underdeveloped. Here, we describe the development of a bis(oxazoline) ligand that enables the desymmetrization of

Identifiers

PMID39807561
PMCPMC11783535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.